Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;107:747-752
Published online before print January 20, 2003, doi: 10.1161/01.CIR.0000049642.20484.5D
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/5/747    most recent
01.CIR.0000049642.20484.5Dv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dahl, M.
Right arrow Articles by Nordestgaard, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahl, M.
Right arrow Articles by Nordestgaard, B. G.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Alpha-1 Antitrypsin Deficiency
*Genetics Home Reference
Related Collections
Right arrow Remodeling
Right arrow Cerebrovascular disease/stroke
Right arrow Brain Circulation and Metabolism
Right arrow Genetics of Stroke
Right arrow Chronic ischemic heart disease
Right arrow Epidemiology
Right arrow Genetics of cardiovascular disease
Right arrow Other Vascular biology

(Circulation. 2003;107:747.)
© 2003 American Heart Association, Inc.


Clinical Investigation and Reports

Blood Pressure, Risk of Ischemic Cerebrovascular and Ischemic Heart Disease, and Longevity in {alpha}1-Antitrypsin Deficiency

The Copenhagen City Heart Study

Morten Dahl, MD; Anne Tybjærg-Hansen, MD, DMSc; Henrik Sillesen, MD, DMSc; Gorm Jensen, MD, DMSc; Rolf Steffensen, MD; Børge G. Nordestgaard, MD, DMSc

From the Department of Clinical Biochemistry, Herlev University Hospital (M.D., B.G.N.), the Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital (A.T.-H.), the Department of Vascular Surgery, Gentofte University Hospital (H.S.), the Department of Medicine B, Hillerød Hospital (R.S.), and the Copenhagen City Heart Study, Bispebjerg University Hospital (A.T.-H., G.J., B.G.N.), Copenhagen, Denmark.

Correspondence to Dr Nordestgaard, Department of Clinical Biochemistry, Herlev University Hospital, DK-2730 Herlev, Denmark. E-mail brno{at}herlevhosp.kbhamt.dk

Background— Because elastase in {alpha}1-antitrypsin deficiency may attack elastin in the arterial wall, we tested whether {alpha}1-antitrypsin deficiency is associated with reduced blood pressure, risk of ischemic cerebrovascular (ICVD) and ischemic heart disease (IHD), and longevity.

Methods and Results— We genotyped 7963 control subjects from the adult general population of Denmark, 1131 Danish patients with ICVD, and 2221 Danish patients with IHD. Compared with MM/MS individuals, systolic blood pressure was lower by 15 mm Hg in ZZ homozygotes (n=6, P=0.03) and 9 mm Hg in MZ heterozygotes with IHD (n=39, P=0.02). Odds ratios for ICVD and IHD in MZ versus MM/MS individuals were 0.70 (0.51 to 0.96) and 0.77 (0.61 to 0.98). Finally, mean ages of MZ and MM/MS control subjects were 58 and 56 years (Mann-Whitney: P=0.008), and relative {alpha}1-antitrypsin MZ genotype frequencies increased from 20 to 93 years among control subjects ({chi}2, P=0.002).

Conclusions— ZZ {alpha}1-antitrypsin deficiency and MZ intermediate deficiency in the context of IHD are associated with reduced blood pressure, and MZ is associated with reduced risk of ICVD and IHD. Because MZ heterozygosity was associated with increased age, MZ heterozygosity could be a beneficial condition.


Key Words: blood pressure • ischemia • heart diseases • stroke • genetics




This article has been cited by other articles:


Home page
ThoraxHome page
M Dahl, B G Nordestgaard, and N Seersholm
{alpha}1-Antitrypsin genotype unaffected by age * Authors' reply
Thorax, March 1, 2005; 60(3): 258 - 259.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. J. Mateos-Caceres, A. Garcia-Mendez, A. Lopez Farre, C. Macaya, A. Nunez, J. Gomez, S. Alonso-Orgaz, C. Carrasco, M. E. Burgos, R. de Andres, et al.
Proteomic analysis of plasma from patients during an acute coronary syndrome
J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1578 - 1583.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Dahl, A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard
A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency
J. Exp. Med., May 17, 2004; 199(10): 1391 - 1399.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M Needham and R A Stockley
{alpha}1-Antitrypsin deficiency * 3: Clinical manifestations and natural history
Thorax, May 1, 2004; 59(5): 441 - 445.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. E. Peppard, T. Young, M. Dahl, A. Tybjaerg-Hansen, B. G. Nordestgaard, P. Lange, J. Vestbo, S. Kony, and M. Zureik
Nose and Blood Pressure
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 317 - 319.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Dahl, A. Tybjaerg-Hansen, B. G. Nordestgaard, P. J Talmud, R. Wright, G. Steiner, M. Syvanne, and S. E Humphries
Risk of Ischemic Heart and Ischemic Cerebrovascular Disease Is not Increased in S, Z, and 11478A {alpha}1-Antitrypsin Carriers of The Copenhagen City Heart Study *
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): e55 - 56.
[Full Text]


Home page
CirculationHome page
A. Pezzini, L. A. Vignolo, A. Padovani, M. Dahl, A. Tybjaerg-Hansen, H. Sillesen, G. Jensen, R. Steffensen, and B. G. Nordestgaard
Risk of Ischemic Cerebrovascular Disease in {alpha}1-Antitrypsin Deficiency * Response
Circulation, August 26, 2003; 108 (8): e62 - e63.
[Full Text] [PDF]